Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease

doi:10.12114/j.issn.1007-9572.2022.0330

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (36): 4595-4600.DOI: 10.12114/j.issn.1007-9572.2022.0330

• Review • Previous Articles Next Articles

Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease

1.School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
2.Department of Rehabilitation Medicine, General Hospital of the Western Theater of the Chinese People's Liberation Army, Chengdu 610083, China
3.Department of Rehabilitation Medicine, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

Received:2022-05-22 Revised:2022-06-25 Published:2022-12-20 Online:2022-09-22
Contact: ZHANG Anren
About author:
CEN Q Y, PANG R Z, CUI Y R, et al. Advances in the mechanism of Lactobacillus rhamnosus GG improving inflammatory bowel disease [J] . Chinese General Practice, 2022, 25 (36) : 4595-4600.

鼠李糖乳杆菌对炎症性肠病的影响机制研究进展

1.610075　四川省成都市，成都中医药大学养生康复学院
2.610083　四川省成都市，中国人民解放军西部战区总医院康复医学科
3.200434　上海市，同济大学附属上海市第四人民医院康复医学科

通讯作者: 张安仁
作者简介:
岑秋宇，庞日朝，崔艳如，等.鼠李糖乳杆菌对炎症性肠病的影响机制研究进展[J].中国全科医学，2022，25（36）：4595-4600. [www.chinagp.net] 作者贡献：岑秋宇进行文章的构思与设计；崔艳如进行文献/资料收集；岑秋宇进行文献/资料整理；岑秋宇撰写论文；魏娟芳进行论文的修订；张安仁、庞日朝负责文章的质量控制及审校；张安仁、庞日朝文章整体负责，监督管理。
基金资助:
国家自然科学基金面上项目(81973927)

Abstract

Abstract:

China is seeing an increasing prevalence of inflammatory bowel disease (IBD) . During the process of exploring treatments for IBD, gut microbiota has been found to be crucial to the development of IBD along with the discovery of microbial-host interactions, suggesting that modulating gut microbiota may be a new strategy for the treatment of IBD. Recent studies have shown that Lactobacillus rhamnosus GG (LGG) , one most widely used probiotic strain, can achieve IBD alleviation by regulating intestinal microbial composition, maintaining intestinal epithelial barrier integrity, modulating intestinal immune response, inhibiting oxidative stress, and improving anxiety-depression status. Therefore, this paper presents a review of the mechanism of action of LGG in improving IBD, providing theoretical support for its clinical application.

Key words: Intestinal diseases, Inflammatory bowel disease, Lactobacillus rhamnosus, Gastrointestinal microbiome, Gut-brain axis

摘要：

炎症性肠病（IBD）在我国的发病率逐年上升。随着微生物-宿主相互作用的发现，人们意识到肠道微生物群对IBD的发生、发展至关重要。由此提示，从调节肠道微生物角度出发，可能是治疗IBD的新策略。鼠李糖乳杆菌（LGG）是目前应用广泛的益生菌菌株之一，其可通过调节肠道微生物组成、维持肠上皮屏障完整性、调节肠道免疫反应、抑制氧化应激、改善焦虑抑郁状态等途径达到缓解IBD的目的。因此，本文就LGG对IBD的作用机制做一综述，以期为其临床应用提供理论支持。

关键词: 肠疾病, 炎症性肠病, 鼠李糖乳杆菌, 胃肠道微生物组, 肠-脑轴

CEN Qiuyu,PANG Rizhao,CUI Yanru, et al. Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease[J]. Chinese General Practice, 2022, 25(36): 4595-4600. DOI: 10.12114/j.issn.1007-9572.2022.0330.
岑秋宇,庞日朝,崔艳如等. 鼠李糖乳杆菌对炎症性肠病的影响机制研究进展[J]. 中国全科医学, 2022, 25(36): 4595-4600. DOI: 10.12114/j.issn.1007-9572.2022.0330.

Figures/Tables 2

References 49

[1]	ORDÁS I, ECKMANN L, TALAMINI M, et al. Ulcerative colitis[J]. Lancet，2012，380(9853):1606-1619. DOI：10.1016/S0140-6736(12)60150-0.
[2]	HODSON R. Inflammatory bowel disease[J]. Nature，2016，540(7634):S97. DOI：10.1038/540S97a.
[3]	ZHANG Y Z, LI Y Y. Inflammatory bowel disease：pathogenesis[J]. World J Gastroenterol，2014，20(1):91-99. DOI：10.3748/wjg.v20.i1.91.
[4]	TORRES J, MEHANDRU S, COLOMBEL J F, et al. Crohn's disease[J]. Lancet，2017，389(10080):1741-1755. DOI：10.1016/S0140-6736(16)31711-1.
[5]	ROUND J L, MAZMANIAN S K. The gut microbiota shapes intestinal immune responses during health and disease[J]. Nat Rev Immunol，2009，9(5):313-323. DOI：10.1038/nri2515.
[6]	KIM D, JUNG J Y, OH H S, et al. Comparison of sampling methods in assessing the microbiome from patients with ulcerative colitis[J]. BMC Gastroenterol，2021，21(1):396. DOI：10.1186/s12876-021-01975-3.
[7]	LEHMANN T, SCHALLERT K, VILCHEZ-VARGAS R, et al. Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis[J]. J Proteomics，2019，201:93-103. DOI：10.1016/j.jprot.2019.04.009.
[8]	FACCHIN S, VITULO N, CALGARO M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease[J]. Neurogastroenterol Motil，2020，32(10):e13914. DOI：10.1111/nmo.13914.
[9]	IMAI T, INOUE R, KAWADA Y, et al. Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease[J]. J Gastroenterol，2019，54(2):149-159. DOI：10.1007/s00535-018-1530-7.
[10]	WEINGARDEN A R, VAUGHN B P. Intestinal microbiota，fecal microbiota transplantation，and inflammatory bowel disease[J]. Gut Microbes，2017，8(3):238-252. DOI：10.1080/19490976.2017.1290757.
[11]	DORON S, SNYDMAN D R, GORBACH S L. Lactobacillus GG：bacteriology and clinical applications[J]. Gastroenterol Clin North Am，2005，34(3):483-498,ix. DOI：10.1016/j.gtc.2005.05.011.
[12]	唐昱婷，汤加勇，赵华. 鼠李糖乳杆菌对肠道屏障功能的影响机制研究进展[J]. 四川农业大学学报，2021，39(4):427-432. DOI：10.16036/j.issn.1000-2650.2021.04.002.
[13]	SEGERS M E, LEBEER S. Towards a better understanding of Lactobacillus rhamnosus GG—host interactions[J]. Microb Cell Fact，2014，13(Suppl 1):S7. DOI：10.1186/1475-2859-13-S1-S7.
[14]	MENTELLA M C, SCALDAFERRI F, PIZZOFERRATO M, et al. Nutrition，IBD and gut microbiota：a review[J]. Nutrients，2020，12(4):E944. DOI：10.3390/nu12040944.
[15]	LANE E R, ZISMAN T L, SUSKIND D L. The microbiota in inflammatory bowel disease：current and therapeutic insights[J]. J Inflamm Res，2017，10:63-73. DOI：10.2147/JIR.S116088.
[16]	NI J, WU G D, ALBENBERG L, et al. Gut microbiota and IBD：causation or correlation? [J]. Nat Rev Gastroenterol Hepatol，2017，14(10):573-584. DOI：10.1038/nrgastro.2017.88.
[17]	TAKAHASHI K, NISHIDA A, FUJIMOTO T, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease[J]. Digestion，2016，93(1):59-65. DOI：10.1159/000441768.
[18]	MIRSEPASI-LAURIDSEN H C, VALLANCE B A, KROGFELT K A, et al. Escherichia coli pathobionts associated with inflammatory bowel disease[J]. Clin Microbiol Rev，2019，32(2):e00060-e00018. DOI：10.1128/CMR.00060-18.
[19]	YEO S, PARK H, SEO E, et al. Anti-inflammatory and gut microbiota modulatory effect of Lactobacillus rhamnosus strain LDTM 7511 in a dextran sulfate sodium-induced colitis murine model[J]. Microorganisms，2020，8(6):E845. DOI：10.3390/microorganisms8060845.
[20]	TONG L J, ZHANG X Y, HAO H N, et al. Lactobacillus rhamnosus GG derived extracellular vesicles modulate gut microbiota and attenuate inflammatory in DSS-induced colitis mice[J]. Nutrients，2021，13(10):3319. DOI：10.3390/nu13103319.
[21]	RALLABANDI H R, YANG H, OH K B, et al. Evaluation of intestinal epithelial barrier function in inflammatory bowel diseases using murine intestinal organoids[J]. Tissue Eng Regen Med，2020，17(5):641-650. DOI：10.1007/s13770-020-00278-0.
[22]	ODENWALD M A, TURNER J R. The intestinal epithelial barrier：a therapeutic target? [J]. Nat Rev Gastroenterol Hepatol，2017，14(1):9-21. DOI：10.1038/nrgastro.2016.169.
[23]	YOO J H, DONOWITZ M. Intestinal enteroids/organoids：a novel platform for drug discovery in inflammatory bowel diseases[J]. World J Gastroenterol，2019，25(30):4125-4147. DOI：10.3748/wjg.v25.i30.4125.
[24]	LEBEER S, CLAES I, TYTGAT H L, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells[J]. Appl Environ Microbiol，2012，78(1):185-193. DOI：10.1128/AEM.06192-11.
[25]	FATMAWATI N N D, GOTOH K, MAYURA I P B, et al. Enhancement of intestinal epithelial barrier function by Weissella confusa F213 and Lactobacillus rhamnosus FBB81 probiotic candidates in an in vitro model of hydrogen peroxide-induced inflammatory bowel disease[J]. BMC Res Notes，2020，13(1):489. DOI：10.1186/s13104-020-05338-1.
[26]	ORLANDO A, LINSALATA M, BIANCO G, et al. Lactobacillus rhamnosus GG protects the epithelial barrier of wistar rats from the pepsin-trypsin-digested gliadin（PTG）-induced enteropathy[J]. Nutrients，2018，10(11):E1698. DOI：10.3390/nu10111698.
[27]	HAN X, LEE A, HUANG S, et al. Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids[J]. Gut Microbes，2019，10(1):59-76. DOI：10.1080/19490976.2018.1479625.
[28]	FIECHTER R H, DE JONG H M, VAN MENS L J J, et al. IL-12p40/IL-23p40 blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and wnt[J]. Front Immunol，2021，12:611656. DOI：10.3389/fimmu.2021.611656.
[29]	YAN F, CAO H W, COVER T L, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism[J]. J Clin Invest，2011，121(6):2242-2253. DOI：10.1172/JCI44031.
[30]	GUAN Q D. A comprehensive review and update on the pathogenesis of inflammatory bowel disease[J]. J Immunol Res，2019，2019:7247238. DOI：10.1155/2019/7247238.
[31]	GEREMIA A, BIANCHERI P, ALLAN P, et al. Innate and adaptive immunity in inflammatory bowel disease[J]. Autoimmun Rev，2014，13(1):3-10. DOI：10.1016/j.autrev.2013.06.004.
[32]	JIN Y B, CAO X, SHI C W, et al. Lactobacillus rhamnosus GG promotes early B lineage development and IgA production in the Lamina propria in piglets[J]. J Immunol，2021，207(8):2179-2191. DOI：10.4049/jimmunol.2100102.
[33]	YANG L Y, HIGGINBOTHAM J N, LIU L P, et al. Production of a functional factor，p40，by Lactobacillus rhamnosus GG is promoted by intestinal epithelial cell-secreted extracellular vesicles[J]. Infect Immun，2019，87(7):e113-119. DOI：10.1128/IAI.00113-19.
[34]	SHEN X, LIU L P, PEEK R M, et al. Supplementation of p40，a Lactobacillus rhamnosus GG-derived protein，in early life promotes epidermal growth factor receptor-dependent intestinal development and long-term health outcomes[J]. Mucosal Immunol，2018，11(5):1316-1328. DOI：10.1038/s41385-018-0034-3.
[35]	WANG Y, GONG L, WU Y P, et al. Oral administration of Lactobacillus rhamnosus GG to newborn piglets augments gut barrier function in pre-weaning piglets[J]. J Zhejiang Univ Sci B，2019，20(2):180-192. DOI：10.1631/jzus.B1800022.
[36]	JIA L, WU R Q, HAN N N, et al. Porphyromonas gingivalis and Lactobacillus rhamnosus GG regulate the Th17/Treg balance in colitis via TLR4 and TLR2[J]. Clin Transl Immunology，2020，9(11):e1213. DOI：10.1002/cti2.1213.
[37]	LI Y B, YANG S J, LUN J X, et al. Inhibitory effects of the Lactobacillus rhamnosus GG effector protein HM0539 on inflammatory response through the TLR4/MyD88/NF-кB axis[J]. Front Immunol，2020，11:551449. DOI：10.3389/fimmu.2020.551449.
[38]	LIU T Y, SONG X L, AN Y P, et al. Lactobacillus rhamnosus GG colonization in early life ameliorates inflammaging of offspring by activating SIRT1/AMPK/PGC-1 α pathway[J]. Oxid Med Cell Longev，2021，2021:3328505. DOI：10.1155/2021/3328505.
[39]	LIU P, LI Y X, WANG R, et al. Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease[J]. Biomedicines，2021，10(1):85. DOI：10.3390/biomedicines10010085.
[40]	BHATTACHARYYA A, CHATTOPADHYAY R, MITRA S, et al. Oxidative stress：an essential factor in the pathogenesis of gastrointestinal mucosal diseases[J]. Physiol Rev，2014，94(2):329-354. DOI：10.1152/physrev.00040.2012.
[41]	GOYAL N, RISHI P, SHUKLA G. Lactobacillus rhamnosus GG antagonizes Giardia intestinalis induced oxidative stress and intestinal disaccharidases：an experimental study[J]. World J Microbiol Biotechnol，2013，29(6):1049-1057. DOI：10.1007/s11274-013-1268-6.
[42]	CHIVERO E T, SIL S, SINGH S, et al. Protective role of Lactobacillus rhamnosus probiotic in reversing cocaine-induced oxidative stress，glial activation and locomotion in mice[J]. J Neuroimmune Pharmacol，2021. DOI：10.1007/s11481-021-10020-9.
[43]	LI J Z, LI Q K, GAO N, et al. Exopolysaccharides produced by Lactobacillus rhamnosus GG alleviate hydrogen peroxide-induced intestinal oxidative damage and apoptosis through the Keap1/Nrf2 and Bax/Bcl-2 pathways in vitro[J]. Food Funct，2021，12(20):9632-9641. DOI：10.1039/d1fo00277e.
[44]	EUGENICOS M P, FERREIRA N B. Psychological factors associated with inflammatory bowel disease[J]. Br Med Bull，2021，138(1):16-28. DOI：10.1093/bmb/ldab010.
[45]	BARBERIO B, ZAMANI M, BLACK C J, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease：a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol，2021，6(5):359-370. DOI：10.1016/S2468-1253(21)00014-5.
[46]	SWEENEY P, O'HARA K, XU Z, et al. HFD-induced energy states-dependent bidirectional control of anxiety levels in mice[J]. Int J Obes（Lond），2017，41(8):1237-1245. DOI：10.1038/ijo.2017.112.
[47]	FOROOZAN P, KOUSHKIE JAHROMI M, NEMATI J, et al. Probiotic supplementation and high-intensity interval training modify anxiety-like behaviors and corticosterone in high-fat diet-induced obesity mice[J]. Nutrients，2021，13(6):1762. DOI：10.3390/nu13061762.
[48]	ZHOU B Q, JIN G, PANG X Q, et al. Lactobacillus rhamnosus GG colonization in early life regulates gut-brain axis and relieves anxiety-like behavior in adulthood[J]. Pharmacol Res，2022，177:106090. DOI：10.1016/j.phrs.2022.106090.
[49]	MEINI S, LAUREANO R, FANI L, et al. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis：case report and review of the literature[J]. Infection，2015，43(6):777-781. DOI：10.1007/s15010-015-0798-2.

研究者	受试样本	丰度降低的肠道菌群	丰度增加的肠道菌群
KIM等^[6]	16例UC患者和15例健康者	Bacteroidetes	Fusobacteria、Proteobacteria
LEHMANN等^[7]	14例UC患者和17例健康者	Phyla Bacteroidetes、Spirochaetes、Tenericutes	—
FACCHIN等^[8]	30例UC患者和18例健康者	Lachnospiraceae、Ruminoclostridium	Clostridium
IMAI等^[9]	20例CD患者和20例健康者	phyla Firmicutes、Bacteroidetes、Faecalibacterium	Enterococcus
LEHMANN等^[7]	11例CD患者和17例健康者	Acidobacteria	—
FACCHIN等^[8]	19例CD患者和18例健康者	Feacalibacterium、Akkermansia、Lachnospiraceae	Anaerotruncus、Oscillospira

研究者	受试样本	丰度降低的肠道菌群	丰度增加的肠道菌群
KIM等^[6]	16例UC患者和15例健康者	Bacteroidetes	Fusobacteria、Proteobacteria
LEHMANN等^[7]	14例UC患者和17例健康者	Phyla Bacteroidetes、Spirochaetes、Tenericutes	—
FACCHIN等^[8]	30例UC患者和18例健康者	Lachnospiraceae、Ruminoclostridium	Clostridium
IMAI等^[9]	20例CD患者和20例健康者	phyla Firmicutes、Bacteroidetes、Faecalibacterium	Enterococcus
LEHMANN等^[7]	11例CD患者和17例健康者	Acidobacteria	—
FACCHIN等^[8]	19例CD患者和18例健康者	Feacalibacterium、Akkermansia、Lachnospiraceae	Anaerotruncus、Oscillospira

Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease

鼠李糖乳杆菌对炎症性肠病的影响机制研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 49

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XU Jun, GAO Yanan, XU Yaxin, YAO Ting, CHEN Yamei. Latent Profiles Analysis and Its Influencing Factors of Disease Burden in Patients with Inflammatory Bowel Disease [J]. Chinese General Practice, 2025, 28(14): 1744-1750.
[2]	LI Yiting, TU Wenjing, YIN Tingting, MEI Ziqi, ZHANG Sumin, WANG Meng, XU Guihua. Application of Artificial Intelligence in Nutritional Management of Patients with Inflammatory Bowel Disease: a Scoping Review [J]. Chinese General Practice, 2025, 28(14): 1709-1716.
[3]	JIANG Rongsheng, ZHANG Long, GUAN Qifan, ZHANG Jing, WU Yuanfeng, LIU Mingjun. Advances in the Role of Short-chain Fatty Acids in Type 2 Diabetes [J]. Chinese General Practice, 2024, 27(24): 3031-3037.
[4]	CHEN Siqi, XIAO Jin, TIAN Siyu, ZHANG Jia, WANG Shuting, ZHANG Xindan, ZHU Yan, CHEN Min. Progress of Research on Mechanism of Intestinal Nervous System Regulating Intestinal Inflammation Based on Intestinal Stem Cells [J]. Chinese General Practice, 2024, 27(23): 2858-2863.
[5]	ZHU Yan, XIAO Jin, YANG Yang, TANG Taichun, WANG Shuting, CHEN Siqi, CHEN Min. Advances in Energy Metabolism Regulation of Intestinal Stem Cell Function and the Therapeutic Advantages of Traditional Chinese Medicine [J]. Chinese General Practice, 2024, 27(23): 2853-2857.
[6]	CHEN Wensheng, LIU Wenming. Research Progress on the Role of Gut Microbiota in the Pathogenesis and Treatment of Sepsis-associated Liver Injury [J]. Chinese General Practice, 2024, 27(21): 2665-2671.
[7]	WANG Fangfang, ZHU Li, XING Jiajia, PANG Rizhao, GOU Xiang, ZHANG Anren. Research Progress on the Changes of Intestinal Barrier and Possible Mechanism after Traumatic Central Nervous System Injury [J]. Chinese General Practice, 2024, 27(14): 1775-1781.
[8]	YIN Tingting, TU Wenjing, ZHANG Sumin, LI Yiting, XU Guihua. Correlation between Food Literacy and Avoidant/Restrictive Food Intake Disorder in Patients with Inflammatory Bowel Disease [J]. Chinese General Practice, 2024, 27(12): 1445-1451.
[9]	LUO Na, RUAN Yanqin, LEI Pingguang, WAN Chonghua, WAN Keyan, SONG Ying, CHEN Ying. Analysis of the Measurement Characteristics of Inflammatory Bowel Disease Patient-reported Outcomes Measurement Scale [J]. Chinese General Practice, 2023, 26(36): 4602-4607.
[10]	BAO Yunli, WANG Zhe, TANG Hairu, LI Na, ZHENG Ying, LI Bin, MA Jun, YU Xiaohui. Disease Burden and Variation Tendency of Inflammatory Bowel Disease in China from 1990 to 2019 [J]. Chinese General Practice, 2023, 26(36): 4581-4586.
[11]	XIAO Liqi, YANG Li, CUI Saixian, ZHANG Yayuan, WANG Yulu, HE Yan. Advances in the Association of High Salt-induced Gut Microbiota Disturbances with Salt-sensitive Blood Pressure [J]. Chinese General Practice, 2023, 26(29): 3704-3709.
[12]	PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703.
[13]	ZHANG Zhendong, CAI Bin, WANG Hongwei, QIAO Zengyong. Study on the Changes of Intestinal Flora and Its Metabolite Phenylacetylglutamine in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(29): 3665-3673.
[14]	CHEN Xiaofen, CHEN Yuhan, MA Juan. Recent Strides in Novel Treatments for Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(27): 3349-3354.
[15]	QIN Yuning, ZHAO Tianyi, LIU Fengbin, WANG Xin, CAO Xue, SUN Minglin, LAI Keyun, DI Luyao, GE Zhishan, LIU Song, XING Ying, YANG Lei, YUE Lihong, ZOU Meimei, HE Liyun, LI Hongjiao. Research of the Measurement Properties of the Chinese Version of the Gastrointestinal Symptom Rating Scale for Patients with Gastrointestinal Diseases [J]. Chinese General Practice, 2023, 26(18): 2277-2285.